The terms of the settlement, which remain subject to government review, provide that Dr Reddy's may exclusively distribute an authorized generic version of Imitrex in the US.
The launch date is expected to be late in the fourth quarter of calendar year 2008, ahead of the expiration of the patent exclusivity on February 6, 2009.
Additional terms of the settlement agreement were not disclosed.
Imitrex is just one of many GlaxoSmithKline's drugs facing competition from the generic market. Zofran and Wellbutrin may also lose their patent protection in the near future.
GlaxoSmithKline's Imitrex tablets had US sales of $890 million for the 12 month period ending June, 2006 according to the statement.